LyGenesis Raises $19M in Series A-2 Funding Led by Prime Movers Lab
Summary
Using lymph nodes as bioreactors to grow ectopic organs is the type of platform technology that could revolutionize the treatment of multiple diseases and beneficially affect millions of lives," said Justin Briggs, Biologist and Partner at Prime Movers Lab, who will be joining LyGenesiss Board of Directors. This biologic therapy is created starting from donated livers, which are processed under Current Good Manufacturing Practice through a multi-step procedure to carefully isolate and suspend the hepatocytes in a solution to ready them for engraftment into that patients mesenteric lymph nodes using an endoscopic ultrasound. LyGenesiss lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). LyGenesiss drug development pipeline includes cell therapies that can produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for end stage renal disease). Portfolio investments span in-space transportation, industrial solar heat, ag tech, neurotechnology, nano-structured materials, wafer slicing, prosthetics, 3D printing, mobility, longevity, drug discovery, and quantum computers.